Cantor Fitzgerald Analysts Cut Earnings Estimates for VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Cantor Fitzgerald lowered their FY2026 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. Cantor Fitzgerald analyst C. Gould now forecasts that the pharmaceutical company will post earnings of $18.33 per share for the year, down from their prior estimate of $18.36. Cantor Fitzgerald currently has a “Overweight” rating and a $485.00 price target on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%. The firm had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the prior year, the firm earned ($12.83) EPS. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year.

Other research analysts have also issued reports about the stock. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Truist Financial set a $490.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. Leerink Partners restated a “market perform” rating and issued a $503.00 price objective (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Morgan Stanley set a $439.00 target price on shares of Vertex Pharmaceuticals and gave the stock an “equal weight” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Thirteen research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $497.10.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $385.65 on Wednesday. The company has a 50-day moving average price of $453.73 and a two-hundred day moving average price of $466.25. Vertex Pharmaceuticals has a twelve month low of $372.35 and a twelve month high of $519.88. The company has a quick ratio of 2.29, a current ratio of 2.52 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $99.03 billion, a PE ratio of 27.57 and a beta of 0.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Activest Wealth Management purchased a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Access Investment Management LLC purchased a new position in Vertex Pharmaceuticals in the second quarter worth about $27,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter worth approximately $32,000. Finally, Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $29,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.